Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa randomized double-blind placebo-controlled study of F573 for liver injury and liver failure
CTR20223199Phase 2Active
- Sponsor
- StarGene
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of F573 in hepatic failure, Drug-induced hepatitis (DILI), Intrahepatic Cholestatic Liver Injury, acute-on-chronic liver failure (ACLF), Chronic Hepatitis B (CHB), sponsored by StarGene. Started Mar 2023; status: active.
02
Drugs
F573
03
Conditions
hepatic failureDrug-induced hepatitis (DILI)Intrahepatic Cholestatic Liver Injuryacute-on-chronic liver failure (ACLF)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20223199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223199.